X

Trial Profile

2015-10: A Phase II Pilot Study of Expanded Natural Killer Cells and Elotuzumab to Eradicate High-Risk Myeloma Post Autologous Stem Cell Transplant

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elotuzumab (Primary) ; Natural killer cell therapy (Primary) ; Melphalan; Nogapendekin alfa inbakicept
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

08 Jul 2020 Planned End Date changed from 1 Aug 2021 to 8 Jul 2020.
08 Jul 2020 Planned primary completion date changed from 1 Aug 2021 to 8 Jul 2020.
08 Jul 2020 Planned initiation date changed from 1 Oct 2019 to 1 Nov 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com